Bispecific Aptamer Sensor toward T-Cell Leukemia Detection in the Tumor Microenvironment.

ACS Omega

Department of Chemistry, Lehman College, The City University of New York, 250 Bedford Park Blvd., West, Bronx, New York 10468, United States.

Published: December 2021

The current detection methods of malignant cells are mainly based on the high expression levels of certain surface proteins on these cells. However, many of the same surface marker proteins are also expressed in normal cells. Growing evidence suggests that the molecular signatures of the tumor microenvironment (TME) are related to the biological state of a diseased cell. Exploiting the unique molecular signature of the TME, we have designed a molecular sensing agent consisting of a molecular switch that can sense the elevated concentration of a small molecule in the TME and promote precise recognition of a malignant cell. We accomplished this by designing and developing a bispecific aptamer that takes advantage of a high concentration of adenosine 5'-triphosphate in the TME. Thus, we report a prototype of a bispecific aptamer molecule, which serves as a dual detection platform and recognizes tumor cells only when a given metabolite concentration is elevated in the TME. This system overcomes hurdles in detecting tumor cells solely based on the elevated expression of cell surface markers, providing a universal platform for tumor targeting and sensing.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8655784PMC
http://dx.doi.org/10.1021/acsomega.1c04125DOI Listing

Publication Analysis

Top Keywords

bispecific aptamer
12
tumor microenvironment
8
tumor cells
8
tumor
5
cells
5
tme
5
aptamer sensor
4
sensor t-cell
4
t-cell leukemia
4
leukemia detection
4

Similar Publications

Bispecific Aptamer-Drug Conjugates Selectively Eliminate Malignant Hematologic Cells for Treating Acute Myeloid Leukemia.

Langmuir

January 2025

Zhejiang Cancer Hospital, The Key Laboratory of Zhejiang Province for Nucleic Acids, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang 310022, China.

Surface antigen-directed immunotherapy is a curative treatment modality for acute myeloid leukemia (AML) that is characterized by the abundance and stability expression of surface antigens. However, current surface antigen-directed immunotherapies have shown poor outcomes and undesirable mortality rates in treating AML patients, primarily due to acquired resistance that arises from using single-target therapies to address the heterogeneous expression of surface antigens. Hence, in order to improve the efficacy of antigen-specific therapies for treating AML, we designed a bispecific aptamer-drug conjugate.

View Article and Find Full Text PDF

Leuco-malachite green (LMG) and leuco-crystal violet (LCV) are widespread co-pollutants in aquatic products that pose a severe threat to human health. Therefore, it is urgent and challenging to develop rapid multiplex detection of LMG and LCV. Herein, the bispecific aptamer (A5b) for LMG and LCV was characterized.

View Article and Find Full Text PDF

Bidirectional Enzyme Inhibition and Activation for In Situ Formation of Injectable Hydrogel Using a Bispecific Aptamer.

Langmuir

December 2024

Department of Biomedical Engineering, The Pennsylvania State University, University Park, Pennsylvania 16802, United States.

Article Synopsis
  • - The study focuses on in situ injectable hydrogels, which are important for applications in regenerative medicine and drug delivery, but face challenges in controlling gelation speed for easier injection.
  • - Researchers investigated a system using bispecific aptamers that can inhibit thrombin (an enzyme involved in clotting) to slow down the formation of fibrin hydrogels.
  • - The study found that when these aptamers interacted with complementary sequences, they could reverse the inhibition, speeding up the hydrogel formation process, demonstrating a new dynamic control for enzyme-mediated hydrogel development.
View Article and Find Full Text PDF

Non-small cell lung cancers (NSCLC) frequently acquire resistance to tyrosine kinase inhibitors (TKI) due to epidermal growth factor receptor (EGFR) mutation or activation of the bypass pathway involving mesenchymal-epithelial transition factor (Met). To address this challenge, a bispecific nanobody-aptamer chimera is designed to target mutated EGFR and Met simultaneously to block their cross-talk in NSCLC. The EGFR-Met chimera is cost-effectively engineered using microbial transglutaminase and click chemistry strategies.

View Article and Find Full Text PDF

The development of novel tools to tackle viral processes has become a central focus in global health, during the COVID-19 pandemic. The spike protein is currently one of the main SARS-CoV-2 targets, owing to its key roles in infectivity and virion formation. In this context, exploring innovative strategies to block the activity of essential factors of SARS-CoV-2, such as spike proteins, will strengthen the capacity to respond to current and future threats.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!